[GRAPHIC OMITTED]



COMPANY CONTACT:
Cytogen Corporation
Stacy Shearer
Investor Relations
(609) 750-8289
sshearer@cytogen.com


                        PATENT INFRINGEMENT SUIT SETTLED

PRINCETON,  N.J., SEPTEMBER 29, 2004 -- Cytogen Corporation (Nasdaq: CYTO) today
announced settlement of a patent infringement suit against Cytogen and C.R. Bard
Inc. for an  undisclosed  payment,  without any admission of fault or liability.
Immunomedics filed suit on February 17, 2000 against Cytogen and Bard,  alleging
that  use  of  Cytogen's   ProstaScint(R)  product  infringed  U.S.  Patent  No.
4,460,559,  which  claims a method for  detecting  and  localizing  tumors.  The
settlement with Immunomedics is on behalf of Cytogen and Bard.

ABOUT CYTOGEN CORPORATION

Founded in 1980,  Cytogen  Corporation  of  Princeton,  NJ is a  product-driven,
oncology-focused  biopharmaceutical  company that develops and  commercializes a
balanced  portfolio of oncology products that address the unmet medical needs of
patients  and  the  physicians  that  serve  them.   Cytogen   directly  markets
QUADRAMET(TM) (samarium Sm-153 lexidronam injection),  PROSTASCINT(R)  (capromab
pendetide) kit for the  preparation  of Indium In-111  capromab  pendetide,  and
NMP22(R)  BLADDERCHEK(R)  (nuclear  matrix  protein-22)  in the  United  States.
Cytogen  has  exclusive   United   States   marketing   rights  to   COMBIDEX(R)
(ferumoxtran-10),  an investigational molecular imaging agent consisting of iron
oxide  nanoparticles  for use in conjunction with magnetic  resonance imaging to
aid in the  differentiation of cancerous and non-cancerous lymph nodes, which is
under  review  by the  U.S.  Food  and  Drug  Administration.  Cytogen  is  also
developing therapeutics targeting  prostate-specific  membrane antigen (PSMA), a
protein  highly  expressed  on the  surface  of  prostate  cancer  cells and the
neovasculature of solid tumors.  Full prescribing  information for the Company's
products is available at www.cytogen.com or by calling 1-800-833-3533.  For more
information, please visit the Company's website at www.cytogen.com, which is not
part of this press release.

THIS PRESS RELEASE  CONTAINS  CERTAIN  "FORWARD-LOOKING"  STATEMENTS  WITHIN THE
MEANING OF THE PRIVATE SECURITIES  LITIGATION REFORM ACT OF 1995 AND SECTION 21E
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  ALL STATEMENTS,  OTHER THAN
STATEMENTS OF  HISTORICAL  FACTS,  INCLUDED IN THIS PRESS RELEASE  REGARDING OUR
STRATEGY,  FUTURE OPERATIONS,  FINANCIAL  POSITION,  FUTURE REVENUES,  PROJECTED
COSTS,  PROSPECTS,  PLANS  AND  OBJECTIVES  OF  MANAGEMENT  ARE  FORWARD-LOOKING
STATEMENTS.  SUCH  FORWARD-LOOKING  STATEMENTS  INVOLVE  A NUMBER  OF RISKS  AND
UNCERTAINTIES  AND INVESTORS ARE CAUTIONED NOT TO PUT ANY UNDUE  RELIANCE ON ANY
FORWARD-LOOKING  STATEMENT.  THERE ARE A NUMBER OF IMPORTANT  FACTORS THAT COULD
CAUSE  CYTOGEN'S  RESULTS  TO DIFFER  MATERIALLY  FROM THOSE  INDICATED  BY SUCH
FORWARD-LOOKING  STATEMENTS.  IN PARTICULAR,  CYTOGEN'S BUSINESS IS SUBJECT TO A
NUMBER OF SIGNIFICANT RISKS, WHICH INCLUDE,  BUT ARE NOT LIMITED TO: THE RISK OF
OBTAINING THE NECESSARY REGULATORY APPROVALS; THE RISK OF




WHETHER PRODUCTS RESULT FROM DEVELOPMENT  ACTIVITIES;  THE RISK OF SHIFTS IN THE
REGULATORY ENVIRONMENT AFFECTING SALES OF CYTOGEN'S PRODUCTS SUCH AS THIRD-PARTY
PAYOR REIMBURSEMENT ISSUES; THE RISK ASSOCIATED WITH CYTOGEN'S DEPENDENCE ON ITS
PARTNERS FOR DEVELOPMENT OF CERTAIN PROJECTS, AS WELL AS OTHER FACTORS EXPRESSED
FROM TIME TO TIME IN CYTOGEN'S PERIODIC FILINGS WITH THE SECURITIES AND EXCHANGE
COMMISSION  (THE  "SEC").  AS A RESULT,  THIS  PRESS  RELEASE  SHOULD BE READ IN
CONJUNCTION WITH CYTOGEN'S  PERIODIC  FILINGS WITH THE SEC. THE  FORWARD-LOOKING
STATEMENTS  CONTAINED HEREIN ARE MADE ONLY AS OF THE DATE OF THIS PRESS RELEASE,
AND CYTOGEN  UNDERTAKES NO OBLIGATION  TO PUBLICLY  UPDATE SUCH  FORWARD-LOOKING
STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCES.

                                       ###